Heyman Tomas J. — SEC insider filings
SEC reporting owner CIK 1814673. 23 insider filings on record with FilingPulse; latest filed 2026-09-28.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2020-12-04 to 2026-09-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 30,544 shares, $1,622,783 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: sale of 26,000 shares @ $54.67 ($1,421,529) in Akero Therapeutics, Inc., filed 2023-06-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Akero Therapeutics, Inc. (AKRO) | Director | 7 | — | 1 leg · 26,000 sh · $1,421,529 | 12 |
| EXELIXIS, INC. (EXEL) | Director | 5 | — | 1 leg · 4,544 sh · $201,254 | 5 |
| OptiNose, Inc. (OPTN) | Director | 6 | — | — | 10 |
| Invivyd, Inc. (IVVD) | Director | 2 | — | — | 2 |
| Xilio Therapeutics, Inc. (XLO) | Director | 2 | — | — | 2 |
| Legend Biotech Corp (LEGN) | Director | 1 | — | — | 1 |
Insider filings — Heyman Tomas J.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-28 | 4 | Legend Biotech Corp (LEGN) | Grant/award (A): 20,986 @ $0 | EDGAR |
| 2026-05-29 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 8,367 @ $0 | EDGAR |
| 2025-12-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) | EDGAR |
| 2025-06-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 9,398 @ $0 | EDGAR |
| 2025-05-30 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 9,812 @ $0 | EDGAR |
| 2025-05-22 | 4 | EXELIXIS, INC. (EXEL) | Sale (S): 4,544 @ $44.29 | EDGAR |
| 2025-05-21 | 4 | OptiNose, Inc. (OPTN) | Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 3,566 (derivative) · Disposition to issuer (D): 2,133 (derivative) · Disposition to issuer (D): 962 (derivative) · Disposition to issuer (D): 1,925 (derivative) | EDGAR |
| 2024-06-11 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | OptiNose, Inc. (OPTN) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 18,838 @ $0 | EDGAR |
| 2023-06-27 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Akero Therapeutics, Inc. (AKRO) | Option exercise (M): 26,000 @ $25.04 · Sale (S): 26,000 @ $54.67 · Option exercise (M): 26,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 13,200 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | OptiNose, Inc. (OPTN) | Grant/award (A): 53,500 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 18,176 @ $0 · Grant/award (A): 36,353 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Invivyd, Inc. (IVVD) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2022-09-16 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 26,400 (derivative) @ $0 | EDGAR |
| 2022-06-24 | 4 | Adagio Therapeutics, Inc. (ADGI) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | OptiNose, Inc. (OPTN) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2022-06-03 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-06-10 | 4 | OptiNose, Inc. (OPTN) | Grant/award (A): 14,439 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2020-12-04 | 4 | OptiNose, Inc. (OPTN) | Grant/award (A): 28,879 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-02 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1814673 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs